Vinegar face masks and barley water? Medieval 'health hacks' mirror today's TikTok trends
The database, called the Corpus of Early Medieval Latin Medicine, offers a wealth of information about how people in the so-called "Dark Ages" viewed health, science and medicine. It was announced by Binghamton University in July.
Meg Leja, an associate professor at the university, told Fox News Digital that she helped catalog hundreds of medieval medical texts, particularly focusing on all surviving Latin manuscripts up to the year 1000.
"This means that we covered most of Continental Europe, but not England, where many early medieval medical writings were in the vernacular (i.e., Old English)," she said.
"Because very few manuscripts survive from before the year 600, effectively our date range is 600 to 1000."
Some of the cures, researchers said, could fit into in modern wellness circles. Below are six examples they found.
Historians repeatedly came across a 12-month detox plan that included drinking herbs like cinnamon, sage, ginger and fennel – one for every month.
The drinks were said to purge the body of buildup like mucus and "unwanted matter," much like modern juice cleanses.
Another recipe in the database recommended a vinegar remedy "so that your face is radiant."
"Grind wheat flour with vinegar [and] put this on as a plaster mixed with oil," the tip advises.
Barley water occasionally pops up on TikTok as a "natural remedy" — and centuries before influencers promoted it, early medieval writers recommended its use.
According to a text written before 1000 A.D., a healer claimed that mixing barley with hot wine would aid digestion.
Other hacks were not TikTok-like at all, featuring ingredients that are both unpleasant and difficult to obtain.
One text written before 1250 swore by dead vultures being a one-size-fits-all cure for a myriad of health issues.
"You capture a vulture and decapitate it with a reed while saying 'Angel, Adonai Abraham, on your account the word is complete,'" the text advises.
The dead bird's skull was said to prevent migraines, while its eyeballs "relieve pain of the eyes." Tying the vulture's feathers to a pregnant woman's legs was also said to help speed up labor.
One late 9th-century tip – found in a priest's personal manuscript – suggested using green lizard ashes for fuller hair.
"For flowing hair, cover the whole head with fresh summer savory and salt and vinegar," the translated instructions read. "[Then] rub it with the ashes of a burnt green lizard, mixed with oil."
The most repulsive recipe, from an 11th-century text, offered the following tip for chest pain.
"You dissolve goat dung in water and, sieved, you give it to drink," the tip advises. "It soon relieves the pain, however intensely it hurt."
J. Matthew Knight, M.D., a board-certified dermatologist and Mohs surgeon, urged caution for those considering trying these cures.
The Florida-based medical expert told Fox News Digital that, while barley, cinnamon and fennel may offer minor digestive benefits, the idea of detoxing over 12 months isn't backed by science.
"When it comes to TikTok trends, or medieval remedies, there is painfully little to no scientific basis for their use."
Knight, the founder of the Knight Dermatology Institute, also noted that the vinegar facial mask "could lead to irritant contact dermatitis," though vinegar has antibacterial effects.
As for the more extreme remedies – like using goat dung for chest pain – the doctor warned they are "unsanitary and dangerous," and emphasized that anyone experiencing chest pain should go straight to the emergency room.
Though Knight said he appreciates the novelty of the list, they exist "somewhere between funny and completely ineffective."
For more Health articles, visit www.foxnews.com/health
"All of these schemes predate the microscope, germ theory of disease and modern medicine, and rely on the idea that maladies were due to spiritual imbalance, moral transgression or cosmic forces," he told Fox News Digital. "Illness wasn't seen as bacterial or viral, but as a disturbance in unseen forces, like 'body humors.'"
"Unfortunately, when it comes to TikTok trends, or medieval remedies, there is painfully little to no scientific basis for their use."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Baroness Amos to lead NHS maternity and neonatal investigation
The Royal College of Midwives (RCM) has welcomed the selection of Baroness Valerie Amos to lead the investigation into NHS maternity and neonatal care, adding it is 'vital' the review gets under way quickly. Baroness Amos was selected by Health Secretary Wes Streeting after bereaved families expressed a preference for someone with distance from the NHS who is able to bring a fresh pair of eyes to the role, the Department of Health and Social Care (DHSC) said. Mr Streeting has been meeting bereaved and harmed families who have been let down by maternity and neonatal services across the country, including in some of the worst affected trusts, DHSC added. In June, he announced that a national investigation into 'systemic' failures in NHS maternity care had been launched by the Government after families were 'gaslit' in their search for the truth. Baroness Amos is master of University College, Oxford, and was a UK Government minister and a senior official at the United Nations. Mr Streeting said: 'I have been appalled by the many harrowing stories I've heard from mothers and fathers let down by the NHS. 'Families asked for fresh eyes, independence and compassion – and that's why I've appointed Baroness Amos. Valerie has an outstanding record of leadership and driving change, nationally and internationally. She will work closely with families to uncover the truth, confront problems and drive the improvements needed so every woman and baby receives safe, high-quality care. 'Through our Plan for Change, we will rebuild the NHS to ensure no family suffers like this again.' Baroness Amos said: 'I will carry the weight of the loss suffered by families with me throughout this investigation. I hope that we will be able to provide the answers that families are seeking and support the NHS in identifying areas of care requiring urgent reform.' The investigation will look at up to 10 services in the country. It will also review the maternity and neonatal system, bringing together the findings of past reviews into one national set of actions, the DHSC said. It will begin work this summer and produce an initial set of national recommendations by December. The 10 maternity and neonatal units will be decided by Baroness Amos and her team, alongside the terms of reference of the investigation, which are being developed with families who have experiences of maternity and neonatal care, including in Leeds, Sussex and Nottingham, the DHSC added. The investigation is separate from the National Maternity and Neonatal Taskforce, which will be made up of a panel of experts and families, and chaired by Mr Streeting. Gill Walton, chief executive of the RCM, said: 'We are pleased to hear of the appointment of Baroness Amos as chair of the rapid review. She has a reputation for taking a thoughtful and strategic approach and we welcome her fresh insight into maternity and neonatal safety. 'It is absolutely vital, though, that this review gets under way quickly. When he announced it in June, we welcomed Wes Streeting's commitment to publishing the review by Christmas, a promise he repeated at the Progress in Partnership summit on maternity and neonatal safety last month. 'However, we are already halfway through August, with no terms of reference, no sense of the trusts who are likely to be part of the review or no clarity on how the review will be conducted. 'Every woman and family should leave maternity and neonatal services whole, happy and healthy, and every member of maternity staff should start and end their shift knowing they have provided safe, good-quality care. 'At the moment, that simply isn't the case. Previous reviews and countless Care Quality Commission reports have flagged the same the systemic failings that are at the heart of the issues facing maternity and neonatal care issues time and time again: unsafe staffing, poor workplace cultures, and not listening to women. 'In spite of that, there has been no forward movement. Wes Streeting promised to change that. Thousands of midwives and maternity support workers, and the whole of the maternity community, are desperate for him to keep that promise and deliver the change we all want to see.' The RCM has also urged the review to look at examples of good maternity care, as well as where services are not meeting standards of care.
Medscape
2 hours ago
- Medscape
Cycling and Education for Hip OA: A Cost-Effective Solution?
TOPLINE: A cycling and education intervention significantly improved self-reported function in hip osteoarthritis (OA) compared with standard physiotherapy. The group-based intervention was also cost-effective, with a cost per quality-adjusted life year below the National Institute for Health and Care Excellence (NICE) threshold. METHODOLOGY: Researchers conducted a pragmatic randomized controlled trial comparing a group-based cycling and education intervention with usual physiotherapy care for hip OA (the CLEAT trial) in Bournemouth, UK. A total of 221 patients (mean age, 64.4 years; 57% women; 98% White) with hip OA, as defined by NICE criteria, who met the primary care criteria for exercise referral were randomly assigned to either cycling against hip pain intervention (CHAIN, 110 participants) or usual physiotherapy care (111 participants). Participants in the cycling group attended an 8-week program comprising education and static cycling sessions at a local leisure center, facilitated by a physiotherapist and a gym instructor, respectively. The physiotherapy group received usual one-to-one care, including exercise, education, and other physiotherapy techniques, at the local hospital or by telephone. The primary outcome was the between-group difference in the self-reported function of performing everyday activities, measured using the Hip Disability and Osteoarthritis Outcome Score (HOOS) activities of daily living subscale at 10 weeks post-treatment. The analysis included a parallel economic evaluation from the perspective of the UK National Health Service (NHS) and personal social services, assessing cost per quality-adjusted life year at 3 months after treatment. TAKEAWAY: Patients in the cycling group showed a significant improvement in the HOOS activities of daily living score at 10 weeks post-treatment compared with those in the physiotherapy group (adjusted mean difference, 6.9; P = .0023). The cycling group experienced improvements in secondary outcomes, with significant increases in scores for symptoms and stiffness (P = .0072), sports (P = .022), and quality of life (P = .042), but no improvement in pain score. No significant differences were observed in physiologic measures such as BMI, blood pressure, or resting heart rate between the cycling and physiotherapy groups. The CHAIN intervention was cost-effective, with a base case analysis cost per quality-adjusted life year of £4092, and showed a high probability of cost-effectiveness at NICE thresholds compared with physiotherapy. IN PRACTICE: "Taken together, these findings add to a growing body of evidence suggesting that, although exercise is beneficial, between-group differences in function and pain are often small when comparing active interventions," the authors of the study wrote. "Although the study did not identify a clinically meaningful between-group difference, CHAIN's cost-effectiveness within the NHS positions it as a viable alternative to usual physiotherapy care," they added. "From the patient's perspective, cycling combined with patient education offers a simple and accessible treatment approach," experts wrote in an accompanying comment. "From the perspective of decision makers, the group-based nature of CHAIN presents a highly cost-effective option for implementation in first-line treatment. Given that a single healthcare provider can deliver this intervention to many patients at a time, CHAIN provides scalability and resource efficiency, which are essential in publicly funded healthcare systems." SOURCE: The study was led by Thomas W. Wainwright, PhD, University Hospitals Dorset NHS Foundation Trust in Bournemouth, UK. It was published online on July 31, 2025, in The Lancet Rheumatology. LIMITATIONS: Most participants did not have radiographic confirmation of OA, affecting baseline severity assessment. The inability to mask participants and treatment providers introduces a risk of performance bias, potentially influencing self-reported outcomes. The exclusion of individuals unable to complete the exercise tolerance test limits applicability to those with lower fitness levels. DISCLOSURES: The study was supported by the Research for Patient Benefit Programme of the National Institute for Health and Care Research. One author disclosed receiving institutional research funding and personal fees, while another author reported receiving royalties and consulting fees from various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Mounjaro weight-loss drug price to almost triple in UK
The price of popular weight-loss jab Mounjaro will nearly triple after the US-owned company equalised costs in markets across the globe. A month's supply of the highest doses of the 'King Kong' of weight loss medicine will rise from £122 to £330 - an increase of 170 per cent. At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight loss jab, via prescriptions from private online pharmacies, according to retailers. In June, the NHS offered Mounjaro to obese patients after health experts calculated from NHS England data that there were 97,500 patients who would benefit from the treatment. Mounjaro's owner Eli Lily said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. The NHS said the price increase would not affect its commissioning of the medicine for people with obesity and type 2 diabetes. Eli Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023. The company said when it launched Mounjaro in the UK, it agreed to a list price "significantly below" that in its three other European markets to prevent delays in availability through the NHS. 'We are now aligning the list price more consistently,' a spokesperson said. The move reflects how the pharmaceutical industry is navigating policy changes in the US, by far its most lucrative market. It comes after Donald Trump's administration complained about 'foreign freeloaders' who rely on the US to pay more for medicine. The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Mr Trump says he wants to narrow this gap to stop Americans from being "ripped off". In the UK, the NHS was told to offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. It came after the National Institute for Health and Care Excellence (Nice) warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. The new 'quality standard' from Nice said NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
